Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Zimmer Biomet Holdings filed a Current Report solely to recast certain financial information and related disclosures included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, originally filed February 20, 2026. In the quarter ended March 31, 2026, the responsibilities of certain senior leaders reporting to the chief operating decision maker changed, as did the related operating profit information those leaders present to the chief operating decision maker.
What each event means for ZBH’s sentiment score is part of Tellvest Pro.
Calendar quarter Q1 2026Earnings call Apr 28, 2026
FY2026 Q1 in brief
Zimmer Biomet delivered Q1 revenue growth of 9.3% reported and 2.9% organic constant currency with adjusted diluted EPS of $2.09 up from $1.81, raising EPS guidance to $8.40-$8.55 and free cash flow growth to 9-11%.
Newest quarter FY2026 Q2 is part of Pro ·
Sources. Tellvest earnings-call sentiment score for Zimmer Biomet (ZBH), FY2026 Q1: 9/10. Scores: Zimmer Biomet’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: ZBH daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
Zimmer Biomet delivered Q1 revenue growth of 9.3% reported and 2.9% organic constant currency with adjusted diluted EPS of $2.09 up from $1.81, raising EPS guidance to $8.40-$8.55 and free cash flow growth to 9-11%. The US salesforce transition progressed as planned while technology and robotics growth accelerated and Paragon 28 growth accelerated toward double digits. The CFO departure was announced and adjusted gross margin reached 73%, with $250M in share repurchases executed in Q1.
Revenue Growth | Competitive Dynamics | Innovation & R&D | Product Launch | Guidance Reliability | M&A | Margin | Trade Tariffs | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 2 | 2 | 1 | 3 | 3 | 2 | 2 | 1 |
| 2025Q1 | 3 | 5 | 3 | 2 | 2 | 2 | 3 | |
| 2025Q2 | 3 | 6 | 6 | 2 | 2 | 3 | 1 | 1 |
| 2025Q3 | 6 | 4 | 3 | 2 | 3 | 1 | 1 | |
| 2025Q4 | 6 | 5 | 1 | 3 | 4 | 2 | 2 | |
| 2026Q1 | 6 | 4 | 3 | 3 | 1 | 1 | 2 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2 | 3 | 3 | 6 | 6 | 6 |
| Competitive Dynamics | 2 | 5 | 6 | 4 | 5 | 4 |
| Innovation & R&D | 1 | 3 | 6 | 3 | 1 | 3 |
| Product Launch | 3 | 2 | 2 | 2 | 3 | 3 |
| Guidance Reliability | 3 | 2 | 2 | 3 | 4 | 1 |
| M&A | 2 | 2 | 3 | 1 | 2 | 1 |
| Margin | 2 | 1 | 1 | 2 | 2 | |
| Trade Tariffs | 1 | 3 | 1 | 1 |
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $2.02B | +4.3% | $1.20 | -40.3% | 71.0% | 19.2% | 11.8% | $421M |
| FY2025 Q1 | $1.91B | +1.1% | $0.91 | +8.3% | 71.2% | 15.3% | 9.5% | $336M |
| FY2025 Q2 | $2.08B | +7.0% | $0.77 | -34.7% | 71.5% | 14.4% | 7.4% | $298M |
| FY2025 Q3 | $2.00B | +9.7% | $1.16 | -5.7% | 72.1% | 17.6% | 11.5% | $546M |
| FY2025 Q4 | $2.24B | +10.9% | $0.70 | -41.7% | 64.7% | 12.8% | 6.2% | $669M |
| FY2026 Q1Selected | $2.09B | +9.3% | $1.22 | +34.1% | 72.4% | 17.9% | 11.4% | $323M |
| FY2026 Q2 | $2.18B | +4.8% | $1.03 | +33.8% | 70.8% | 15.0% | 9.1% | $484M |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.
| Analyst | Firm | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Travis Steed | Bank of America | 7 questions · 29% challenging |
| Robbie Marcus | JPMorgan | 7 questions · 14% challenging |
| Rick Wise | Stifel | 6 questions · 0% challenging |
| Larry Biegelsen | Wells Fargo | 6 questions · 33% challenging |
| David Roman | Goldman Sachs | 5 questions · 60% challenging |
| Patrick Wood | UBS | 5 questions · 0% challenging |
| Matt Miksic |
GAAP revenue YoY +9.30% → base 7. The base score is anchored to the GAAP revenue YoY band before transcript, EPS, and guidance adjustments.
| Barclays |
| 5 questions · 0% challenging |
| Caitlin Cronin | Canaccord Genuity | 5 questions · 0% challenging |
| Matt Taylor | Jefferies | 5 questions · 0% challenging |
| Joanne Wuensch | Citigroup | 4 questions · 0% challenging |
| Firm | Analysts | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| UBS | 2 analysts | 9 questions · 0% challenging |
| JPMorgan | 1 analyst | 7 questions · 14% challenging |
| Bank of America | 1 analyst | 7 questions · 29% challenging |
| Stifel | 1 analyst | 6 questions · 0% challenging |
| Wells Fargo | 1 analyst | 6 questions · 33% challenging |
| Barclays | 1 analyst | 5 questions · 0% challenging |
| Canaccord Genuity | 1 analyst | 5 questions · 0% challenging |
| Goldman Sachs | 1 analyst | 5 questions · 60% challenging |
What ZBH and other companies said about each other on FY2026 Q1 earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“We love what we're seeing with our partnership with Finsurgical and TMINI.”
Zimmer Biomet highlights a positive partnership with Finsurgical tied to its TMINI mini-robotics platform.
“There was a Kaiser strike in the West Coast where we had the highest share in knees.”
A labor strike at Kaiser on the West Coast disrupted knee procedure volumes where Zimmer Biomet holds high share, a signal on Kaiser's operational disruption.
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
ZBH Zimmer Biomet | 9 | +9.3% | |
| ABT Abbott Laboratories | 6 | +7.8% | |
| ALGN Align Technology | 6 | +6.2% | |
| BSX Boston Scientific | 6 | +11.6% | |
| DXCM DexCom | 9 | +15.1% | |
| EW Edwards Lifesciences | 9 | +16.7% | |
| MDT Medtronic | 7 | +8.8% | |
| PODD Insulet Corporation | 8 | +33.9% | |
| STE Steris | 7 | +7.3% | |
| SYK Stryker Corporation | 4 | +2.6% |